Format
Sort by

Send to

Choose Destination

Links from Books

Items: 13

1.

[99mTc(CO)3]+-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a hexa-histidine tag (H6) on the C-terminal.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 20 [updated 2011 Jan 20].

2.

[99mTc(CO)3]+-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a hexa-histidine tag (H6) on the N-terminal.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 16 [updated 2011 Jan 20].

3.

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

Tolmachev V, Hofström C, Malmberg J, Ahlgren S, Hosseinimehr SJ, Sandström M, Abrahmsén L, Orlova A, Gräslund T.

Bioconjug Chem. 2010 Nov 17;21(11):2013-22. doi: 10.1021/bc1002357. Epub 2010 Oct 22.

PMID:
20964447
4.

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.

Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, Hansson M, Wennborg A, Orlova A.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):613-22. doi: 10.1007/s00259-009-1283-x. Epub 2009 Oct 17.

PMID:
19838701
5.

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.

J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.

6.

Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.

Ekblad T, Orlova A, Feldwisch J, Wennborg A, Karlström AE, Tolmachev V.

Bioorg Med Chem Lett. 2009 Jul 15;19(14):3912-4. doi: 10.1016/j.bmcl.2009.03.083. Epub 2009 Mar 25.

PMID:
19364646
7.

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.

Tolmachev V, Friedman M, Sandström M, Eriksson TL, Rosik D, Hodik M, Ståhl S, Frejd FY, Orlova A.

J Nucl Med. 2009 Feb;50(2):274-83. doi: 10.2967/jnumed.108.055525. Epub 2009 Jan 21.

8.

Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.

Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V.

Bioconjug Chem. 2008 Jan;19(1):235-43. doi: 10.1021/bc700307y. Epub 2007 Dec 29.

PMID:
18163536
9.

Update: affibody molecules for molecular imaging and therapy for cancer.

Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V.

Cancer Biother Radiopharm. 2007 Oct;22(5):573-84. Review.

PMID:
17979560
10.

Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY.

Cancer Res. 2006 Apr 15;66(8):4339-48.

11.

Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.

Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J, Tolmachev V.

J Nucl Med. 2006 Mar;47(3):512-9.

12.

Engineered antibody fragments and the rise of single domains.

Holliger P, Hudson PJ.

Nat Biotechnol. 2005 Sep;23(9):1126-36. Review.

PMID:
16151406
13.

An affibody in complex with a target protein: structure and coupled folding.

Wahlberg E, Lendel C, Helgstrand M, Allard P, Dincbas-Renqvist V, Hedqvist A, Berglund H, Nygren PA, Härd T.

Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3185-90. Epub 2003 Feb 19.

Items per page

Supplemental Content

Write to the Help Desk